Legend Biotech and Novartis Partner in Exclusive License Deal for CAR-T Therapies
Legend Biotech recently announced the successful closing of a license transaction with Novartis for certain chimeric antigen receptor T-cell (CAR-T) therapies. This exclusive partnership between Legend Biotech and Novartis marks a significant milestone in the field of biotechnology and cell therapy. The pharmaceutical industry has been witnessing remarkable advancements in the field of biotechnology, particularly…